Yamanouchi Pharmaceutical Co. said Thursday its group pretax profit fell 5.8 percent to 100.02 billion yen in fiscal 2001 due to a rise in research and development costs and a decline in sales and royalty revenues abroad for its antigastritis medicine.

But the Tokyo-based pharmaceutical company said its group net profit rose 36.7 percent to 55.16 billion yen, mainly because it stopped paying corporate and other taxes with its Irish unit on licensing deals for its antiulcer drugs.

Group per-share net profit came to 154.73 yen, up from 111.80 yen.

Consolidated sales rose 5.1 percent to 481.33 billion yen.

Yamanouchi said it will pay an annual dividend of 25 yen, including 15 yen at yearend, both unchanged from the previous year.

For the current fiscal year, Yamanouchi expects to log a consolidated pretax profit of 96 billion yen and net profit of 51 billion yen on consolidated sales of 510 billion yen.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.